REPLICor is a biopharmaceutical company developing first-in-class entry inhibitors for the treatment of hepatitis C (HCV) and prevention of HCV re-infection following liver transplantation. The company also targets the hepatitis B and influenza markets. The lead compound REP 9AC is a broad-spectrum antiviral having potent activity against HCV, HBV, influenza and other enveloped viruses. The compound is active by multiple routes of administration and is well tolerated. The company business strategy is to enter into alliances with major biopharmaceutical companies in order to further develop and market its product.